Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that its innovation division, Innovenn, has commenced production of its pioneering product Labskin at their new state of the art laboratory facilities in the UK.

 

Labskin, a human skin equivalent, allows high quality skin research to be carried out in the sponsors own facilities. Unlike most skin models, Labskin provides an environment similar to human skin in that it can house microflora.

 

The commencement of production at these new facilities marks a milestone for Innovenn as they have sought to streamline operations to deal with larger order volumes and a wider geographic distribution. Innovenn have also recently recruited additional technical staff to assist with production and order fulfillment.

 

Tony Richardson, CEO of Venn Life Sciences commented: “We are delighted to be able to offer our clients one of the most exciting skin research products ahead of schedule from our facilities in York. We will continue to work and build capacity in order to increase our worldwide distribution of Labskin and the provision of associated microbiology services.”

 

Enquiries:

 

Venn Life Sciences Holdings Plc www.vennlifesciences.com
Tony Richardson, Chief Executive Officer Tel: +353 154 99 341
Declan Service, Managing Director

Orla McGuinness, Marketing Manager

Tel: +353 877705506
   
Zeus Capital (Nominated Adviser and Broker)  
Ross Andrews/Andrew Jones (Corporate Finance) Tel: 0161 831 1512
Dominic Wilson (Institutional Sales) Tel: 020 7533 7727
   
Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303

 

About InnoVenn

InnoVenn (55.6% owned by Venn) is a market development accelerator dedicated to rapidly commercialising proven scientific breakthroughs in the form of products and technologies primarily in Skin Science. These include Labskin the breakthrough research grade human skin testing platform as well as the clinically proven Blemish Control Technology for the professional skincare market. For more information on Innovenn, visit www.innovenn.co.uk

 

About Venn Life Sciences Limited

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutionsto pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation – Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division – Innovenn – focused primarily on breakthrough development opportunities in Skin Science.